Delaware Court Rules Against Novo Nordisk in Wegovy Patent Case, Highlighting Challenges in Method-of-Treatment Claims
核心洞察
The District of Delaware dismissed Novo Nordisk's patent infringement claim against Mylan's generic Wegovy application, ruling that method-of-treatment claims must align precisely with FDA-approved drug labels.
The court found that Mylan's proposed generic label did not instruct physicians to avoid all therapeutic agents when prescribing semaglutide, contradicting Novo's patent claim requiring administration "without another therapeutic agent."
The decision underscores the critical importance for pharmaceutical companies to ensure patent claim limitations match approved drug labeling, as prosecution amendments can later limit enforceability in generic drug disputes.
The District of Delaware has delivered a significant setback to Novo Nordisk in its patent dispute with Mylan over generic versions of the blockbuster weight-loss drug Wegovy, highlighting critical challenges pharmaceutical companies face when pursuing method-of-treatment patent claims that don't align with FDA-approved labeling.
Court Rejects Patent Infringement Claims
The court dismissed Novo Nordisk's infringement claim regarding U.S. Patent No. 9,764,003, which covers a method of reducing body weight by administering semaglutide "without another therapeutic agent." This patent limitation, originally added during prosecution to overcome a Section 103(a) obviousness rejection, became the central issue in Mylan's successful Motion to Dismiss.
Novo Nordisk argued that Mylan's proposed generic label discouraged coadministration with other drugs, implying intent to induce infringement. The company pointed to specific label warnings against combining semaglutide with other GLP-1 agonists or semaglutide-containing products, cautions about coadministration with other weight-loss drugs, and advice to "consider reducing" insulin doses to mitigate hypoglycemia (搜索) risk.
However, the court found these arguments insufficient, stating that "the label does not state, imply, or suggest in any way that Mylan's semaglutide product should be administered without any other therapeutic agent." Instead, the court noted that Mylan's label acknowledged and anticipated coadministration with other drugs, including insulin and antihypertensives.
Induced Infringement Standards in ANDA Cases
The case centered on induced infringement under 35 U.S.C. § 271(b), which requires demonstrating that a defendant actively and knowingly encouraged others to perform the patented method. In Abbreviated New Drug Application (ANDA) cases, the proposed generic label serves as the primary evidence of intent, since the generic product isn't yet marketed and real-world usage data isn't available.
The court rejected Novo's argument that physicians would "inevitably" prescribe semaglutide alone, emphasizing that inducement requires active encouragement rather than mere foreseeability of the claimed method's practice.
Implications for Patent Strategy
The decision provides several critical lessons for pharmaceutical patent prosecution and enforcement. The court's ruling demonstrates that method-of-treatment claims with limitations not reflected in FDA-approved labels face significant enforceability challenges. Patent prosecution amendments made to overcome prior art rejections can later become liabilities if they don't align with a drug's approved use.
The case also underscores the evidentiary burden in ANDA litigation, where labels often represent the only available evidence of intent. These labels must clearly support the claimed method to establish induced infringement.
Wegovy Market Impact
Novo Nordisk manufactures Wegovy, described as one of the blockbuster GLP-1 receptor (搜索) agonists approved for weight management (搜索). Mylan's ANDA seeks approval for a generic version of this highly successful medication. The lawsuit originally asserted five patents, with the dismissed patent representing a key component of Novo's intellectual property protection strategy.
The ruling emphasizes that even when physicians are highly likely to practice a claimed method of treatment, patent holders must demonstrate that generic labels actively encourage the specific patented method. This standard creates substantial challenges for pharmaceutical companies seeking to extend market exclusivity through method-of-treatment patents that include limitations not clearly supported by approved labeling.